Antares Pharma Inc (NASDAQ:ATRS)
| 4.10 Data as of Jun 18 |  +0.01 / +0.24%Today’s Change | 3.33 Today|||52-Week Range 5.58 | +7.61% Year-to-Date |
Latest ATRS News | Press Releases
| Identifying the Biggest Gem in Antares's Pipeline Jun 13 / MotleyFool.com |
Today’s Trading
| Previous close | 4.09 |
| Today’s open | 4.07 |
| Day’s range | 4.05 - 4.14 |
| Volume | 674,692 |
| Average volume (3 months) | 970,631 |
| Market cap | $516.1M |
| Dividend yield | -- |
Data as of 4:00pm ET, 06/18/2013
Growth & Valuation
| Earnings growth (last year) | -100.00% |
| Earnings growth (this year) | -16.00% |
| Earnings growth (next 5 years) | +65.00% |
| Revenue growth (last year) | +37.17% |
| P/E ratio | NM |
| Price/Sales | 18.60 |
| Price/Book | 5.95 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SQNMSequenom Inc | -0.13 | -3.01% |
| CSIICardiovascular Syste... | -0.32 | -1.43% |
| MMSIMerit Medical System... | +0.28 | +2.50% |
| ATRIAtrion Corp | +2.10 | +0.96% |
Data as of 4:00pm ET, 06/18/2013
Financials
| Next reporting date | August 15, 2013 |
| EPS forecast (this quarter) | -$0.03 |
| Annual revenue (last year) | $22.6M |
| Annual profit (last year) | -$11.4M |
| Net profit margin | -50.62% |
Profile
Sector Health Technology |
Industry Medical Specialties |
President, Chief Executive Officer & Director Paul K. Wotton, PhD, MBA |
Chief Financial Officer, Secretary, & Executive VP Robert F. Apple, CPA |
Corporate headquarters Ewing, New Jersey |
Forecasts
